YME1L1 Antibody

What is YME1L1 and what is its primary function in cellular biology?

YME1L1 (YME1-like 1) is an ATP-dependent zinc metalloprotease localized in the mitochondria. It plays a critical role in regulating mitochondrial morphology and protein metabolism. YME1L1 was first identified in yeast through a screen for gene products that increase mitochondrial DNA migration to the nucleus .

Key functions include:

• Cleaving OPA1 at position S2, which promotes maintenance of normal mitochondrial structure

• Ensuring cell proliferation and maintaining normal cristae morphology

• Promoting antiapoptotic activity and protecting mitochondria from accumulation of oxidatively damaged membrane proteins

• Regulating mitochondrial adaptation in response to various cellular signals

• Catalyzing degradation of folded and unfolded proteins with suitable degron sequences in the mitochondrial intermembrane region

What are the typical molecular weights observed for YME1L1 and why might I see different bands on Western blot?

YME1L1 exists in multiple forms, which explains the appearance of different bands on Western blots:

The variation in observed molecular weights results from:

• Processing of the mitochondrial targeting sequence (MTS) upon import into mitochondria

• Nuclear-encoded YME1L1 requires cleavage of the MTS from premature YME1L1 (~80 kDa) to produce the mature protein (~63 kDa)

• YME1L1 has three isoforms produced by alternative splicing with molecular weights of 86 kDa, 80 kDa, and 76 kDa

Which applications are validated for YME1L1 antibodies?

Based on multiple scientific validation studies, YME1L1 antibodies have been successfully used in:

What are the recommended dilutions for different YME1L1 antibody applications?

Optimal dilutions vary by application and specific antibody. Based on validated protocols:

Always titrate antibodies in your specific experimental system to obtain optimal results, as recommended dilutions may vary between different lots and manufacturers .

How should I validate YME1L1 antibody specificity for my research?

A comprehensive validation approach includes:

• Knockdown/Knockout controls: Use YME1L1 shRNA or CRISPR/Cas9-mediated knockout cells as negative controls. Multiple studies have utilized YME1L1 shRNA (e.g., shYME1L-seq1 and shYME1L-seq2) and YME1L1-/- HeLa cells generated by CRISPR/Cas9 .

• Overexpression controls: Express tagged YME1L1 (wild-type or mutant variants) and verify co-detection with the YME1L1 antibody. Several studies have used transiently expressed YME1L1 and YME1L1 R149W in YME1L1-/- cells .

• Molecular weight verification: Confirm detection at the expected molecular weight (mature form ~63 kDa, precursor ~80 kDa) .

• Subcellular localization: Verify mitochondrial localization using co-staining with mitochondrial markers like ATPase subunit β .

• Multiple antibodies: Compare results using antibodies targeting different epitopes within YME1L1 to confirm consistency .

What experimental controls should I include when studying YME1L1?

When designing YME1L1 experiments, include these essential controls:

• Positive controls: Use cell lines with known YME1L1 expression (HeLa, MCF-7, A549, HEK-293) .

• Negative controls:

  • YME1L1 knockout/knockdown cells (YME1L1-/- HeLa cells, shRNA-treated cells)

  • Primary antibody omission control

  • Isotype control (e.g., Rabbit IgG or Mouse IgG1 depending on host species)

• Functional controls:

  • Include wild-type and mutant forms (e.g., YME1L1 R149W) for comparison

  • Use proteasome inhibitors to assess stability (cycloheximide chase experiments)

  • Include catalytically inactive mutants (e.g., YME1L1 E381Q) to distinguish between active and inactive forms

• Processing controls: To study precursor processing, examine both wild-type YME1L1 and processing mutants (e.g., R149W) .

How can I distinguish between precursor and mature forms of YME1L1?

To effectively differentiate between YME1L1 forms:

• Gradient gel electrophoresis: Use 6-10% gradient gels to better separate the ~80 kDa precursor from the ~63 kDa mature form .

• Mitochondrial fractionation: Isolate mitochondria using differential centrifugation (e.g., 16,000 g for 10 minutes at 4°C) to enrich for mature YME1L1 .

• Combined mutations: Generate constructs combining the R149W mutation with catalytic site mutations (e.g., E381Q) to stabilize precursor forms .

• In vitro processing assays: Use cell-free synthesis of 35S-labeled precursor proteins and incubate with purified mitochondrial processing peptidase (MPP) to analyze processing efficiency .

• Time-course experiments: Perform pulse-chase experiments with cycloheximide to monitor precursor processing over time .

What are effective approaches for studying YME1L1's role in mitochondrial morphology?

To investigate YME1L1's impact on mitochondrial dynamics:

• Live-cell imaging: Transfect cells with mitochondrial markers (e.g., mito-GFP) and perform time-lapse microscopy using spinning disc confocal or super-resolution microscopy .

• Morphological analysis: Score mitochondrial morphology in fixed cells using fluorescent microscopy. Categorize morphology (e.g., tubular, fragmented, or intermediate) and quantify the percentage of cells with each morphology .

• Genetic manipulation: Compare YME1L1 knockdown/knockout with rescue experiments using wild-type or mutant YME1L1 (e.g., R149W). Analyze at least 100 GFP-positive fixed cells per condition .

• OPA1 processing analysis: Monitor OPA1 isoforms by Western blot, as YME1L1 cleaves OPA1 at S2 position, generating forms crucial for mitochondrial structure maintenance .

• Electron microscopy: Examine cristae morphology ultrastructurally to assess YME1L1's impact on mitochondrial inner membrane organization .

How can I analyze YME1L1 complex formation and assembly?

To study YME1L1 complex assembly:

• Sucrose gradient centrifugation: Apply mitochondrial lysates to a 5-25% sucrose gradient and perform ultracentrifugation (71,000 x g for 16 h at 4°C). Collect fractions and analyze by Western blot. YME1L1 typically assembles into complexes of ~2 MDa .

• Blue native PAGE: Solubilize mitochondria with digitonin or n-dodecyl β-D-maltoside and analyze complex formation by blue native gel electrophoresis.

• Co-immunoprecipitation: Use YME1L1 antibodies to pull down the complex and identify interacting partners by mass spectrometry or Western blot .

• Comparative analysis: Assess complex formation between wild-type YME1L1 and mutant variants (e.g., R149W, E381Q, or R149W/E381Q) to determine the impact of mutations on assembly .

• Crosslinking studies: Apply chemical crosslinkers to stabilize transient protein-protein interactions within the YME1L1 complex before analysis.

Why might I see no signal when detecting YME1L1 in Western blot?

When troubleshooting absence of YME1L1 signal:

• Protein extraction method: YME1L1 is a mitochondrial membrane protein requiring effective extraction. Try:

  • Using stronger lysis buffers containing 1% Triton X-100 or 0.5-1% SDS

  • Including protease inhibitors to prevent degradation

  • Performing mitochondrial enrichment before extraction

• Sample preparation:

  • Avoid repeated freeze-thaw cycles of protein samples

  • Heat samples at 70°C instead of 95°C to prevent aggregation of membrane proteins

  • Use fresh samples when possible

• Antibody selection:

  • Ensure the antibody recognizes the species being studied

  • Verify the epitope location - if targeting regions affected by processing (aa 1-150), you may miss mature YME1L1

  • Try antibodies targeting different regions (e.g., aa 350-600 vs. aa 550-700)

• Detection system:

  • Try more sensitive detection methods (e.g., chemiluminescence vs. colorimetric)

  • Increase exposure time

  • Use signal enhancers specific for low-abundance proteins

How can I optimize immunofluorescence detection of YME1L1?

For improved YME1L1 immunofluorescence:

• Fixation optimization:

  • Compare different fixatives (4% paraformaldehyde vs. methanol fixation)

  • For mitochondrial proteins, test mild permeabilization (0.1% Triton X-100 for 5-10 minutes)

• Antigen retrieval:

  • Try heat-mediated antigen retrieval with citrate buffer (pH 6.0) or TE buffer (pH 9.0)

  • Optimize retrieval time (10-20 minutes) based on signal strength

• Signal amplification:

  • Use tyramide signal amplification for low abundance targets

  • Try biotin-streptavidin amplification systems

  • Consider secondary antibodies with brighter fluorophores

• Imaging optimization:

  • Use confocal or spinning disc microscopy for better resolution of mitochondrial structures

  • Try deconvolution or super-resolution techniques for detailed analysis

  • Co-stain with established mitochondrial markers (Tom20, ATPase subunit β)

• Controls and validation:

  • Always include a YME1L1 knockout/knockdown control

  • Use structured illumination microscopy for colocalization studies

  • For live cell imaging, consider photobleaching controls

What might cause unexpected bands when using YME1L1 antibodies?

When investigating unexpected bands:

• Processing intermediates:

  • YME1L1 undergoes processing from ~80 kDa precursor to ~63 kDa mature form

  • Multiple intermediates may appear during processing or degradation

  • Combination mutations (e.g., R149W/E381Q) can stabilize processing intermediates

• Isoforms:

  • YME1L1 has three isoforms from alternative splicing (86 kDa, 80 kDa, 76 kDa)

  • Different antibodies may detect specific isoforms based on epitope location

• Post-translational modifications:

  • Phosphorylation or other modifications may cause mobility shifts

  • Under stress conditions, YME1L1 function and processing can be altered

• Cross-reactivity:

  • Confirm specificity using knockout/knockdown controls

  • Try alternative antibodies targeting different epitopes

  • Perform peptide competition assays to confirm specificity

• Degradation products:

  • Include fresh protease inhibitors in all buffers

  • Process samples quickly and maintain cold temperatures

  • Avoid repeated freeze-thaw cycles

By addressing these common issues with methodological rigor, researchers can optimize YME1L1 antibody use for more reliable and reproducible results in both basic and advanced research applications.

How should I design experiments to study YME1L1 mutations associated with mitochondriopathy?

To investigate YME1L1-related diseases:

• Patient-derived cell models:

  • Use fibroblasts from patients with YME1L1 mutations (e.g., R149W) to study endogenous effects

  • Compare mitochondrial morphology, respiratory function, and OPA1 processing between patient and control cells

• CRISPR/Cas9 gene editing:

  • Generate isogenic cell lines with specific YME1L1 mutations (e.g., R149W)

  • Create YME1L1 knockout cells for rescue experiments with wild-type or mutant variants

• Functional complementation assays:

  • Express wild-type YME1L1 in patient-derived cells to assess rescue of phenotypes

  • Compare different mutations to establish genotype-phenotype correlations

• Animal models:

  • Develop conditional knockout models to avoid embryonic lethality

  • Create knock-in models of specific mutations (e.g., R149W)

  • Use tissue-specific promoters to study effects in relevant tissues (e.g., optic nerve)

• Mitochondrial function assessment:

  • Measure oxygen consumption rate (OCR) using Seahorse analyzer

  • Assess membrane potential using fluorescent dyes (TMRM, JC-1)

  • Quantify ATP production and mitochondrial reactive oxygen species

What methodological approaches can I use to study YME1L1's role in cancer progression?

For cancer-related YME1L1 research:

• Expression analysis in tumor samples:

  • Compare YME1L1 mRNA and protein levels between tumor (T) and adjacent normal (N) tissues

  • Analyze expression across different cancer stages and correlate with clinical outcomes

• Functional manipulation in cancer cells:

  • Use shRNA (e.g., shYME1L-seq1, shYME1L-seq2) for stable knockdown

  • Apply CRISPR/Cas9 for complete knockout

  • Perform rescue experiments with wild-type or mutant YME1L1

• Signaling pathway analysis:

  • Investigate YME1L1's impact on Akt-mTOR activation in cancer cells

  • Assess effects on mitochondrial metabolism in glycolytic vs. oxidative cancer cells

• Tumor growth assays:

  • Perform xenograft experiments with YME1L1-manipulated cancer cells

  • Use adeno-associated virus (AAV) expressing YME1L1 shRNA for in vivo knockdown

  • Monitor tumor growth, invasion, and metastasis

• Therapeutic targeting evaluation:

  • Test sensitivity to mitochondrial inhibitors in YME1L1-high vs. YME1L1-low cancer cells

  • Evaluate combination approaches targeting YME1L1 and related pathways